A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

• Status: Recruiting
• Trial end date: 2024-11-07

Summary

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-95251 in subjects with advanced cancers.

• Phase: Phase 1

Details

• Lead Sponsor: Celgene
• Treatments: Antibodies; Antibodies, Monoclonal; Cetuximab; Immunoglobulins; Rituximab